In the last trading session, 1.0 million shares of the Evaxion Biotech A/S ADR (NASDAQ:EVAX) were traded, and its beta was -0.31. Most recently the company’s share price was $0.96, and it changed around -$0.1 or -9.63% from the last close, which brings the market valuation of the company to $5.18M. EVAX currently trades at a discount to its 52-week high of $13.61, offering almost -1317.71% off that amount. The share price’s 52-week low was $0.84, which indicates that the current value has risen by an impressive 12.5% since then. We note from Evaxion Biotech A/S ADR’s average daily trading volume that its 10-day average is 1.63 million shares, with the 3-month average coming to 300.95K.
Evaxion Biotech A/S ADR stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 2 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended EVAX as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight. Evaxion Biotech A/S ADR is expected to report earnings per share of -0.03 for the current quarter.
Evaxion Biotech A/S ADR (NASDAQ:EVAX) trade information
Instantly EVAX has showed a red trend with a performance of -9.63% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 1.2200 on recent trading dayincreased the stock’s daily price by 21.31%. The company’s shares are currently down -86.03% year-to-date, but still up 4.12% over the last five days. On the other hand, Evaxion Biotech A/S ADR (NASDAQ:EVAX) is -38.99% down in the 30-day period. We can see from the shorts that 0.12 million shares have been sold at a short interest cover period of 1.64 day(s).
Evaxion Biotech A/S ADR (EVAX) estimates and forecasts
Evaxion Biotech A/S ADR share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -66.74 percent over the past six months and at a 81.48% annual growth rate that is well above the industry average of 16.70%.
Consensus estimates provided by 2 financial analysts predict the company will bring in an average of 1.66M in revenue for the current quarter. 1 analysts expect Evaxion Biotech A/S ADR to make 3.2M in revenue for the current ending quarter. Forecasts for the next quarter put sales growth at 6,174.51%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -18.88%.
EVAX Dividends
Evaxion Biotech A/S ADR’s next quarterly earnings report is expected to be released in January.
